- Metabolic Stability
- CYP Interaction
- Permeability & Transporters
- Physicochemical Properties
- Protein Binding
Discovery PK and Toxicology
Exton, PA – September 8, 2015 – Frontage, a full service contract research organization (CRO), today announced the appointment of Michael S. Willett, PharmD., RAC as President of its clinical business unit.
Exton, PA – May 5, 2015 – Frontage, a full service contract research organization (CRO), today announced the opening of its newest facility in Secaucus, NJ to expand its clinical research portfolio of services.
Exton, P.A. – September 9, 2014 – Frontage Labs has received a grant award of $2.44m from the New Jersey Economic Development Authority. As part of Grow New Jersey Assistance Program, the incentive grant will be used for construction and capital investments involving a 36,000 square foot facility in Secaucus, NJ; to support Phase I-III clinical research.
Exton, P.A. – August 22, 2014 – Frontage today announced recognition by INC Magazine in the INC 5000. For the second time in three years, Frontage earned a spot on the magazine’s thirty-third annual compilation of America’s fastest-growing privately-held companies. Qualifying organizations must demonstrate consistent year-on-year revenue growth and future potential success. In the past three years, the company has achieved nearly 50% revenue growth and added close to 100 new positions. Among companies listed in the greater Philadelphia area, Frontage ranked sixteenth position for new jobs creation.
Exton, P.A., (July 30, 2014) – Hangzhou Tigermed Consulting Co., Ltd. and Frontage Laboratories, Inc. today announced completion of the previously announced investment agreement, following approval by the China Securities and Regulatory Commission. Tigermed, a leading provider of outsourced clinical development services across China and Asia Pacific regions to the pharmaceutical and medical device industries has acquired a majority position in the ownership of Frontage, a recognized leader in bioanalysis, preclinical studies, early phase clinical studies and product development services for biopharmaceutical organizations.